BNP Paribas Exane Upgrades Adient (ADNT) to Outperform

BNP Paribas Exane analyst James Picariello upgraded Adient (NYSE: ADNT) from Neutral to Outperform with a price target of $26.00.

For an analyst ratings summary and ratings history on Adient click here. For more ratings news on Adient click here.

Shares of Adient closed at $21.58 yesterday.

You May Also Be Interested In

• Kepler Cheuvreux Upgrades Entain PLC (ENT:LN) (GMVHF) to Buy
• Piper Sandler Upgrades Capricor Therapeutics (CAPR) to Overweight 'Ahead of Extended 11/22 PDUFA Date'
• BofA Securities Upgrades Timken (TKR) to Buy, 'Early innings of a transformation story'